 |
1 Company | 1 Product |
|
|
1 Product | |
0 Diseases | |
2 Trials |  |
13 News |  |
| «123456789101112 |
- | Journal: Dynamic regulation of HIV-1 capsid interaction with the restriction factor TRIM5α identified by magic-angle spinning NMR and molecular dynamics simulations. (Pubmed Central) - May 2, 2019
Taken together, our results suggest that TRIM5α uses several mechanisms to destabilize the capsid lattice, ultimately inducing its disassembly. Our findings add to a growing body of work indicating that dynamic allostery plays a pivotal role in capsid assembly and HIV-1 infectivity.
- | Journal: Crystal Structure of the Capsid Protein from Zika Virus. (Pubmed Central) - Apr 26, 2019
Furthermore, the highly positively charged interface, mainly formed by α4 helix, is proposed to be responsible for nucleotide binding. These findings will greatly enhance our understanding of ZIKV C protein, providing information for anti-ZIKV drug design targeting the C protein.
- | Journal: Cetylpyridinium chloride interaction with the Hepatitis B virus core protein inhibits capsid assembly. (Pubmed Central) - Apr 26, 2019
Taken together, our results show that CPC inhibits capsid assembly and leads to reduced HBV biogenesis. Thus, CPC is an effective pharmacological agent that can reduce HBV particles.
- | Journal: Atmospheric Spectroscopy and Photochemistry at Environmental Water Interfaces. (Pubmed Central) - Apr 13, 2019
Expected final online publication date for the Annual Review of Physical Chemistry Volume 70 is April 20, 2019. Please see http://www.annualreviews.org/page/journal/pubdates for revised estimates.
- | Journal: Inhibitors of the HIV-1 capsid, a target of opportunity. (Pubmed Central) - Apr 9, 2019
Small molecules that bind to the viral capsid protein can be potent inhibitors of HIV infection. Capsid-targeting drugs are predicted to exhibit high barriers to viral resistance, and ongoing work in this area is contributing to an understanding of the molecular biology of HIV uncoating and maturation.
- | Journal: Modular, bioorthogonal strategy for the controlled loading of car-go into a protein nanocage. (Pubmed Central) - Apr 7, 2019
In a subsequent reaction, the proteins could be modified further with a fluorophore using the tetrazine ligation. The applica-tion of capsid assembly conditions on the functionalized proteins led to successful particle formation, show-ing the potential of this covalent encapsulation strategy.
- | Journal: Bombyx mori nucleopolyhedrovirus orf133 and orf134 are involved in the embedding of occlusion-derived viruses into polyhedra. (Pubmed Central) - Mar 29, 2019
Confocal microscopy analysis showed that Bm133 and Bm134 distributed throughout the whole cell during viral infection and Bm134 concentrated on the mature polyhedra in lysed cells. These results suggest that although Bm133 and Bm134 are not essential for BV or ODV development, they play vital roles in polyhedra morphogenesis.
- | Journal: Mutations in the nucleocapsid protein were complemented by mutations in the L protein to restore viral RNA synthesis. (Pubmed Central) - Mar 29, 2019
This mechanism of action allows the sequestered RNA to be released locally without disrupting the overall structure of the nucleocapsid. Since this flexible structural motif is present in the N proteins of many NSVs, release of the sequestered RNA genome by local conformational changes in the N protein may be a general mechanism in NSV viral RNA synthesis.
- | Journal: 5-Aminothiophene-2,4-dicarboxamide analogues as hepatitis B virus capsid assembly effectors. (Pubmed Central) - Mar 28, 2019
In the end, these medicinal chemistry efforts led to the identification of multiple analogues strongly binding to Cp, potently inhibiting HBV replication in nanomolar range without cytotoxicity, and exhibiting good oral bioavailability (F). Two of our analogues, 19o (EC = 0.11 μM, CC > 100 μM, F = 25%) and 19k (EC = 0.31 μM, CC > 100 μM, F = 46%), displayed overall lead profiles superior to reported CAEs 7-10 used in our studies.
- | Preclinical, Journal: Design and synthesis of aminothiazole based Hepatitis B Virus (HBV) capsid inhibitors. (Pubmed Central) - Mar 28, 2019
This compound exerted potent inhibitory effect upon HBV production, either in cell culture or in mice with no obvious acute toxicity. We propose that further development of this compound could lead to novel potent anti-HBV inhibitors that target HBV capsid assembly.